IP Library › Granted Patent US 8,557,994
Granted Patent B2
US 8,557,994 · App. 12/804,621 · Granted Oct 15, 2013

Deuterium-enriched pyridinonecarboxamides and derivatives

Inventor: Daljit Singh Dhanoa (Del Mar, CA)
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,557,994
App. No.
12/804,621
Granted
Oct 15, 2013
Kind
B2
Abstract

The present invention relates to deuterium-enriched pyridinone carboxamides and their derivatives of the formula I, and pharmaceutically acceptable salts thereof, are partial or full agonists of serotonin (5-Hydroxytryptamine or 5-HT 4 ) receptor subtype 4, and are useful compounds for the prevention and treatment of Alzheimer's disease, cognitive and memory dysfunction, mild cognition impairment, memory decline, cognitive impairment associated with schizophrenia, cognitive impairment associated with age-related dementia or Alzheimer's disease, cognitive impairment associated with post-coronary bypass surgery, attention deficit hyperactivity disorder, speech improvement in autistic children, sleep apnea in Alzheimer's patients, irritable bowel syndrome, gastroesophageal reflux disease, Crobn's disease, emesis, nausea, vomiting, prokinesia, non-ulcer dyspepcia, anxiety, depression, pain, migraine, urinary incontinence, arterial fibrillation, arrhythmia, ischemic stroke, gastric emptying disorders, gastritis, gastrointestinal disorders, feeding disorders, obesity, anorexia, constipation, respiratory depression, and erectile dysfunction.

Claims (10)

1. A deuterium enriched compound selected from the group consisting of:

6,7-Dihydro-4-hydroxy-7-isopropyl(d7)-6-oxo-N-(3-(piperidin(d10)-1-yl)propyl)thieno[2,3-b]pyridine-5-carboxamide

2,3-dideutero-6,7-Dihydro-4-hydroxy-7-isopropyl(d7)-6-oxo-N-(3-(piperidin(d10)-1-yl)prop[r]yl)thien[2,3-b]pyridine-5-carboxamide

2,3-dideutero-6,7-Dihydro-4-hydroxy-7-isopropyl-6-oxo-N-(3-(piperidin(d10)-1-yl)propyl-d1)thieno[2,3-b]pyridine-5-carboxamide

2,3-dideutero-6,7-Dihydro-4-hydroxy-7-isopropyl(d7)-6-oxo-N-(3-(piperidin(d10)-1-yl)propyl-d4)thieno[2,3-b]pyridine-5-carboxamide

and the pharmaceutically acceptable salts thereof.

2. The compound of claim 1 , 6,7-Dihydro-4-hydroxy-7-isopropyl(d 7 )-6-oxo-N-(3-(piperidin(d 10 )-1-yl)propyl)thieno[2,3-b]pyridine-5-carboxamide as the potassium salt

3. The compound of claim 1 , 2,3-dideutero-6,7-Dihydro-4-hydroxy-7-isopropyl(d 7 )-6-oxo-N-(3-(piperidin(d 10 )-1-yl)prop[r]yl)thien[2,3-b]pyridine-5-carboxamide as the potassium salt thereof.

4. The compound of claim 1 , 2,3-dideutero-6,7-Dihydro-4-hydroxy-7-isopropyl-6-oxo-N-(3-(piperidin(d10)-1-yl)propyl-d1)thieno[2,3-b]pyridine-5-carboxamide, as the potassium salt thereof

5. The compound of claim 1 , 2,3-dideutero-6,7-Dihydro-4-hydroxy-7-isopropyl(d 7 )-6-oxo-N-(3-(piperidin(d 10 )-1-yl)propyl-d 4 )thieno[2,3-b]pyridine-5-carboxamide as the potassium salt thereof

Continuity (2)
Provisional Application 61271720 · Jul 27, 2009
Related Publication 20110021557A1 · Jan 27, 2011